Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026

Barinthus Biotherapeutics plc.

Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.
Cash, cash equivalents & restricted cash $71.9M at Dec 31, 2025, down from $112.4M YoY.
Net loss of $66.5M ($1.64 per share) in 2025 vs $61.1M ($1.55) in 2024.
R&D expenses decreased to $25.6M from $42.2M due to deprioritization of legacy assets.
VTP-1000 multiple ascending dose data in celiac expected H2 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Barinthus Biotherapeutics plc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 13, 2026, Barinthus Biotherapeutics plc (the “Company”) provided an overview of the Company’s progress and announced its financial results for the year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.